therapy

Diagnosis and treatment of mental disturbances in patients with hematological disorders

MENTAL DISTURBANCES IN HEMATOLOGICAL DISORDERS , , ,

D.E. Vybornykh and V.G. Savchenko

Hematology Research Center, RF Ministry of Health, Moscow, Russian Federation

ABSTRACT

Mental disturbances emerged in patients with hematological disorders are discussed. Such conditions are categorized into somatogenic psychoses (n = 118) and psychogenic (nozogenic) reactions (n = 192). A subgroup of somatogenic psychoses consisted of delirium (n = 73; 61.9 %) and endogenomorphic psychoses (n = 38; 32.2 %) which included hallucinatory-paranoid states (n = 19; 50 %), depressive-delusional states (n = 16; 42.1 %), oneiroids (n = 3; 7.9 %), and psychogenically-induced schizophrenia episodes (n = 7; 5.9 %). A subgroup of nozogenic reactions included neurotic states: anxiety-dissociative (n = 67; 34.9 %), anxiety-phobic (n = 42; 21.8 %), affective (depressive-anxiety, n = 51; 26.6 %, hypomanic, n = 3; 1.6 %), schizophrenic (dissociative, n = 19; 9.9 %, anxiety-coenestopatic n = 10; 5.2 %). Therapeutic techniques for relief of symptomatic psychoses and nozogenic reactions in the studied patients were developed. These techniques included administration of psychotropic agents prescribed depending on the clinical presentation of the disorder and possible side effects, as well as the psychotherapeutic methods aimed at improving patients’ adherence to treatment.

Keywords: hematological disorders, psychoses, nozogenic reactions, therapy.

Read in PDF (RUS)pdficon

References

  1. Целибеев Б.А. Психические нарушения при соматических заболеваниях. М., 1972. Tselibeyev B.A. Psikhicheskiye narusheniya pri somaticheskikh zabolevaniyakh [Mental disturbances in somatic disorders]. M., 1972.
  2. Prieto J.M., Blanch J., Atala J. et al. Psychiatric morbidity and impact on hospital length of stay among hematological cancer patients receiving stem-cell transplantation. J. Clin. Oncol. 2002; 20: 1907–17.
  3. Дробижев М.Ю. Нозогении (психогенные реакции) при соматических заболеваниях: Дис. … д-ра мед. наук. М., 2000. [Drobizhev M.Yu. Nozogenii (psikhogennye reaktsii) pri somaticheskikh zabolevaniyakh: Dis. … d-ra med. nauk (Nozogenies (psychogenic reactions) in somatic disorders: Author’s summary of dissertation for the degree of DSci). M., 2000.]
  4. Смулевич А.Б., Фильц А.О., Гусейнов И.Г. и др. К проблеме нозогений. В кн.: Ипохондрия и соматоформные расстройства. М., 1992: 111–23. [Smulevich A.B., Filts A.O., Guseynov I.G. i dr. K probleme nozogeniy. V kn.: Ipokhondriya i somatoformnye rasstroystva (On problem of nozogeny. In: Hypochondriasis and somatoform disorders). M., 1992: 111–23.]
  5. Зверев В.В. Психопатологические расстройства при множественной миеломе. В сб.: Психосоматические и соматоформные расстройства в современной клинической практике. Мат-лы межрегиональной науч.-практ. конф. Иркутск, 2005: 42–3. [Zverev V.V. Psikhopatologicheskiye rasstroystva pri mnozhestvennoy miyelome. V sb.: Psikhosomaticheskiye i somatoformnye rasstroystva v sovremennoy klinicheskoy praktike. Mat-ly mezhregionalnoy nauch.-prakt. konf (Psychopathological disorders in multiple myeloma. In: Psychosomatic and somatogorm disorders in current clinical practice. Materials of inter-regional scientific-and-practical conference). Irkutsk, 2005: 42–3.]
  6. Ибрагимова С.З. Психопатологические расстройства при острых лейкозах и пути коррекции: Дис. … канд. мед. наук. Ташкент, 2009. [Ibragimova S.Z. Psikhopatologicheskiye rasstroystva pri ostrykh leykozakh i puti korrektsii: Dis. … kand. med. nauk (Psychopathological disorders in acute leukemias and therapeutic approaches: Author’s summary of dissertation for the degree of PhD). Tashkent, 2009.]
  7. Hosaka T., Aoki T., Ichikawa Y. Emotional states of patients with hematological malignancies: preliminary study. Jpn. J. Clin. Oncol. 1994; 24(4): 186–90.
  8. Смулевич А.Б., Сыркин А.Л., Дробижев М.Ю. и др. Психокардиология. М., 2005. [Smulevich A.B., Syrkin A.L., Drobizhev M.Yu. i dr. Psikhokardiologiya (Psychocardiology). M., 2005.]
  9. Бурлаков А.В. Психозы послеоперационного периода вмешательств на открытом сердце (аспекты клиники и терапии). Психиатрия 2005; 3: 45–51. [Burlakov A.V. Psikhozy posleoperatsionnogo perioda vmeshatelstv na otkrytom serdtse (aspekty kliniki i terapii) (Psychoses in post-operation period after open heart surgery (clinical and therapeutic aspects. In: Psychiatry). Psikhiatriya 2005; 3: 45–51.]
  10. Целибеев Б.А., Яшиш И.Л., Окунев В.Н. Психические нарушения при гематологических заболеваниях. Журн. неврол. и психиатр. 1964; 64(8): 1192–7. [Tselibeyev B.A., Yashish I.L., Okunev V.N. Psikhicheskiye narusheniya pri gematologicheskikh zabolevaniyakh (Mental disturbances in hematological disorders. In: Journ. of neurol. & psychiatry). Zhurn. nevrol. i psikhiatr. 1964; 64(8): 1192–7.]
  11. Magen J.G., D’Mello D. Acute lymphocytic leukemia and psychosis: treatment with electroconvulsive therapy. Ann. Clin. Psychiat. 1995; 7: 133–7.
  12. Liptzin B. What criteria should be used for the diagnosis of delirium? Dement. Geriatr. Cogn. Disord. 1999; 10(5): 364–7.
  13. O’Keeffe S.T. Clinical subtypes of delirium in the elderly. Dement. Geriatr. Cogn. Disord. 1999; 10(5): 380–5.
  14. Руководство по психиатрии. Т. 1. Под ред. А.С. Тиганова. М., 1999. [Rukovodstvo po psikhiatrii. T. 1. Pod red. A.S. Tiganova (Manual of psychiatry. Ed. by: A.S. Tiganov). M., 1999.]
  15. Rodin G., Voshart K. Depression in the medically ill: an overview. Am. J. Psychiat. 1986; 143: 696–705.
  16. Фелинская Н.И. Современное учение о реактивных состояниях и узловые вопросы этой проблемы (критический обзор). Журн. неврол. и психиатр. 1980; 80(11): 1717–29. [Felinskaya N.I. Sovremennoye ucheniye o reaktivnykh sostoyaniyakh i uzlovye voprosy etoy problemy (kriticheskiy obzor) (Current teaching on reactive states and key issues of this problem (critical review). In: Journ. of neurol. & psychiatry). Zhurn. nevrol. i psikhiatr. 1980; 80(11): 1717–29.]
  17. Hurtado F., Martin G., Sanz M.A. Leukemia and mental health: psychological disturbances, predisposing actors, precipitating conditions and psychotherapeutic approach. Sangr. Barc. 1993; 38: 429–34.
  18. Lloyd G.G., Parker A.C., Ludlam C.A. et al. Emotional impact of diagnosis and early treatment of lymphomas. J. Psychosom. Res. 1984; 28: 157–62.
  19. Самушия М.А., Мустафина Е.А. Нозогении (психогенные реакции) у женщин со злокачественными опухолями органов репродуктивной си- стемы. Псих. расстройства в общей мед. 2007; 2: 11–6. [Samushiya M.A., Mustafina Ye.A. Nozogenii (psikhogennye reaktsii) u zhenshchin so zlokachestvennymi opukholyami organov reproduktivnoy (Nozogenies (psychogenic reactions) in women with reproductive system malignancies. In: Mental disorders in general med.). Psikh. rasstroystva v obshchey med. 2007; 2: 11–6.]
  20. Скрябин Д.C. Нозогенные реакции при раке поджелудочной железы. Псих. расстройства в общей мед. 2009; 4: 9–16. [Skryabin D.C. Nozogennye reaktsii pri rake podzheludochnoy zhelezy (Nozogenic reactions in pancreatic cancer. In: Mental disorders in general med.). Psikh. rasstroystva v obshchey med. 2009; 4: 9–16.]
  21. Смулевич А.Б., Иванов С.В., Бескова Д.А. и др. Нозогенные реакции у больных раком желудка. Псих. расстройства в общей мед. 2007; 2(3): 4–10. [Smulevich A.B., Ivanov S.V., Beskova D.A. i dr. Nozogennye reaktsii u bolnykh rakom zheludka (Nozogenic reactions in patients with stomach cancer. In: Mental disorders in general med.). Psikh. rasstroystva v obshchey med. 2007; 2(3): 4–10.]
  22. Barsky A.J., Klerman G.L. Overview: hypochondriasis, bodily complaints, and somatic styles. Am. J. Psychiat. 1983; 140(3): 273–83.
  23. Снежневский А.В. Общая психопатология: курс лекций. Валдай, 1970. Snezhnevskiy A.V. Obshchaya psikhopatologiya: kurs lektsiy [General psychopathology: course of lectures]. Valday, 1970.
  24. Смулевич А.Б., Тхостов А.Ш., Сыркин А.Л. и др. Клинические и пси- хологические аспекты реакции на болезнь (к проблеме нозогений). Журн. неврол. и психиатр. 1997; 97(2): 4–9. [Smulevich A.B., Tkhostov A.Sh., Syrkin A.L. i dr. Klinicheskiye i psikhologicheskiye aspekty reaktsii na bolezn (k probleme nozogeniy) (Clinical and psychological aspects of reaction to disease (on problem of nozogeny). In: Journ of neurol. & psychiatry). Zhurn. nevrol. i psikhiatr. 1997; 97(2): 4–9.]
  25. Tolle R. Somatopsychic aspects of paranoia. Psychopatology 1993; 26: 127–37.
  26. Cloninger C.R. Anxiety and theories of emotion. In: Handbook of anxiety: Classification, etiological factors and associated disturbances. Vol. 2. Amsterdam: Elsevier, 1988: 1–29.
  27. Иванов С.В. Соматоформные расстройства (органные неврозы): эпидемиология, коморбидные психосоматические соотношения, терапия: Дис. … д-ра мед. наук. М., 2002. [Ivanov S.V. Somatoformnye rasstroystva (organnyye nevrozy): epidemiologiya, komorbidnye psikhosomaticheskiye sootnosheniya, terapiya: Dis. … d-ra med nauk (Somatoform disorders (organic neuroses): epidemiology, comorbid psychosomatic relationships, therapy: Author’s summary of dissertation for the degree of DSci). M., 2002.
  28. Petrilowitsch N. Abnorme Persoenlichkeiten. Basel, New-York: S. Karger, 1960: 65–70.
  29. Кречмер Э. Строение тела и характер. М., 1995: 219–27. [Krechmer E. Stroyeniye tela i kharakter (Body build and personality). M., 1995: 219–27.]
  30. Бурлаков А.В. Шизофрения и расстройства шизофренического спектра, коморбидные сердечно-сосудистой патологии (клиника, психосоматические соотношения, терапия): Дис. … канд. мед. наук. М., 2008. [Burlakov A.V. Shizofreniya i rasstroystva shizofrenicheskogo spektra, komorbidnye serdechno-sosudistoy patologii (klinika, psikhosomaticheskiye sootnosheniya, terapiya): Dis. … kand. med. nauk (Schizophrenia schizophrenia spectrum disorders comorbid with cardiovascular diseases (symptoms, psychosomatic relationships, and therapy): Author’s summary of dissertation for the degree of PhD). M., 2008.]
  31. Ильина Н.А., Бурлаков А.В. Шизофренические нозогенные реакции у пациентов с тяжелой сердечно-сосудистой патологией. Аспекты типо- логии и предикции. Психиатрия (науч.-практ. журн.) 2005; 1(13): 7–16. [Ilina N.A., Burlakov A.V. Shizofrenicheskiye nozogennyye reaktsii u patsiyentov s tyazheloy serdechno-sosudistoy patologiyey. Aspekty tipologii i prediktsii (Schizophrenic nozogenic reactions in patients with severe cardiovascular diseases. Aspects of typology and prediction. In: Psychiatry (scientif.-and-pract. journ). Psikhiatriya (nauch.-prakt. zhurn.) 2005; 1(13): 7–16.]
  32. Буренина Н.И. Психопатологическая дифференциация патологиче- ских телесных сенсаций. Журн. неврол. и психиатр. 1997; 5: 22–6. Burenina N.I. Psikhopatologicheskaya differentsiatsiya patologicheskikh telesnykh sensatsiy [Psychopathological differentiation of pathological body sensations. In: Journ. of neurol. & psychiatry]. Zhurn. nevrol. i psikhiatr. 1997; 5: 22–6.
  33. Shontz F. Body image and its disorders. Inter. J. Psychiat. Med. 1974; 5(4): 27–48.
  34. Воробьев В.Ю. Шизофренический дефект (на модели шизофрении, протекающей с преобладанием негативных расстройств): Дис. … д-ра мед. наук. М., 1988. [Vorobyev V.Yu. Shizofrenicheskiy defekt (na modeli shizofrenii, protekayushchey s preobladaniyem negativnykh rasstroystv): Dis. … d-ra med. nauk (Schizophrenic defect (on model of schizophrenia with predominant negative symptons): Author’s summary of dissertation for the degree of DSci). M., 1988.]
  35. Смулевич А.Б. Малопрогредиентная шизофрения и пограничные состояния. М., 1987. [Smulevich A.B. Maloprogrediyentnaya shizofreniya i pogranichnye sostoyaniya (Low-progredient schizophrenia and borderline states). M., 1987.]
  36. Смулевич А.Б. Психическая патология и ишемическая болезнь сердца (к проблеме нозогений). В кн.: Психические расстройства и сер- дечно-сосудистая патология. Под ред. А.Б. Смулевича, А.Л. Сыркина. М., 1994: 12–9. [Smulevich A.B. Psikhicheskaya patologiya i ishemicheskaya bolezn serdtsa (k probleme nozogeniy). V kn.: Psikhicheskiye rasstroystva i serdechnososudistaya patologiya. Pod red. A.B. Smulevicha, A.L. Syrkina (Mental disorders and ischemic cardiac disease (on problem on nozogeny). In: Mental disorders and cardiovascular disesases. Ed. by: A.B. Smulevich, A.L. Syrkin). M., 1994: 12–9.]
  37. Huber G. Indizen fur die Somatosehypothese bei den Schizophrenien. Fortschr. Neurol. Psychiat. 1976; 44(3): 77–94.
  38. Внуков В.А. О дефекте при шизофреническом процессе. Сб. трудов II Всесоюзного съезда психиатров и невропатологов. М., 1937: 466–70. [Vnukov V.A. O defekte pri shizofrenicheskom protsesse. Sb. trudov II Vsesoyuznogo syezda psikhiatrov i nevropatologov (On defect in schizophrenia process. In: Coll. of works of 2nd All-Union congress of psychiatrists and nuerologists). M., 1937: 466–70.]
  39. Бажин Е.Ф., Гнездилов А.В. Психофармакологические и психокор- рекционные аспекты реабилитации онкологических больных. Реабили- тация онкологических больных. М., 1988: 46–65. [Bazhin Ye.F., Gnezdilov A.V. Psikhofarmakologicheskiye i psikhokorrektsionnye aspekty reabilitatsii onkologicheskikh bolnykh. Reabilitatsiya onkologicheskikh bolnykh (Psychopharmacological and psychocorrectional aspects of rehabilitation of cancer patients. In: Rehabilitation of cancer patients). M., 1988: 46–65.]
  40. Бутылина Н.В. Посмертная судебно-психиатрическая экспертиза лиц с онкологическими заболеваниями в гражданском процессе: Дис. … канд. мед. наук. М., 1999. [Butylina N.V. Posmertnaya sudebno-psikhiatricheskaya ekspertiza lits s onkologicheskimi zabolevaniyami v grazhdanskom protsesse: Dis. … kand. med. nauk (Postmortem forensic assessment of persons with tumors in civil process: Author’s summary of dissertation for the degree of PhD). M., 1999]
  41. Черепкова Е.В. Клиника и динамика психических расстройств у онкобольных с раком различных локализаций: Автореф. дис. … канд. мед. наук. Новосибирск, 2002. [Cherepkova Ye.V. Klinika i dinamika psikhicheskikh rasstroystv u onkobolnykh s rakom razlichnykh lokalizatsiy: Avtoref. dis. … kand. med. nauk (Clinical presentation and course of mental disorders in patients with cancer of various locations: Author’s summary of dissertation for the degree of PhD). Novosibirsk, 2002.]
  42. Adler R., Herrman J., Kehle K. (eds.) Psychosomatische Medizin. Munchen, 1996.
  43. Akechi T., Nakano T., Okamura H. et al. Psychiatric Disorders in Cancer Patients: Descriptive Analysis of 1721 Psychiatric Referrals at Two Japanese Cancer Center Hospitals. Jpn. J. Clin. Oncol. 2001; 31(5): 188–94.
  44. Durkin I., Kearney M., O’Siorain L. Psychiatric disorder in a palliative care unit. Palliative Med. 2003; 17: 212–8.
  45. Goldacre M.J., Kurina L.M., Wotton C.J. et al. Schizophrenia and cancer: an epidemiological study. Br. J. Psychiat. 2005; 187: 334–8.
  46. Massie M.J. Prevalence of Depression in Patients With Cancer. J. Natl. Cancer Inst. Monogr. 2004; 32: 57–71.
  47. Selye H. Stress and disease. Science 1955; 122: 625–37.
  48. Литвицкий П.Ф. Психиатрия чрезвычайных ситуаций: Руководство. Т. 1. Под ред. Т.Б. Дмитриевой. М., 2004. [Litvitskiy P.F. Psikhiatriya chrezvychaynykh situatsiy: Rukovodstvo. T. 1. Pod red. T.B. Dmitriyevoy (Psychiatry of emergencies: Manual. Vol. 1. Ed. by: T.B. Dmitriyeva). M., 2004.]
  49. Смулевич А.Б., Сыркин А.Л., Дробижев М.Ю. и др. Психокардио- логия. М., 2005. [Smulevich A.B., Syrkin A.L., Drobizhev M.Yu. i dr. Psikhokardiologiya (Psychocardiology). M., 2005.]
  50. dos Santos M.J., Pimentel P., Monteiro J.M. et al. Psychiatric disorders in hospitalized patients with hematologic neoplasms. Acta Med. Port. 1991; 4(1): 5–8.
  51. Sasaki T., Akaho R., Sakamaki H. et al. Mental disturbances during isolation in bone marrow transplant patients with leukemia. Bone Marrow Transplant. 2000; 25(3): 315–8.
  52. Ahles T.A., Silberfarb P.M., Herndon J. et al. Psychologic and neuropsychologic functioning of patients with limited small-cell lung cancer treated with chemotherapy and radiation therapy with or without warfarin: a study by the Cancer and Leukemia Group B. J. Clin. Oncol. 1998; 16: 1954–60.
  53. Gath D., Cooper P., Day A. Hysterectomy and psychiatric disorder: I. Levels of psychiatric morbidity before and after hysterectomy. Br. J. Psychiat. 1982; 140: 335–42.
  54. Green A.I., Austin C.P. Psychopathology of pancreatic cancer. A psychobiologic probe. Psychosomatics 1993; 34: 208–21.
  55. Okamura M., Yamawaki S., Akechi T. et al. Psychiatric Disorders Following First Breast Cancer Recurrence: Prevalence, Associated Factors and Relationship to Quality of Life. Jpn. J. Clin. Oncol. 2005; 35: 302–9.
  56. Strauss D.S., Spitzer R.L., Muskin P.R. Maladaptive denial of physical illness: a proposal for DSM-IV. Am. J. Psychiat. 1990; 147(9): 1168–72.
  57. Холланд Дж., Леско Л., Фрейдин Ю.Л. и др. Опыт введения в со- временную психоонкологию. Независимый психиатр. журн. 1995; 4: 9–17. [Kholland Dzh., Lesko L., Freydin Yu.L. i dr. Opyt vvedeniya v sovremennuyu psikhoonkologiyu (Experience of introduction to modern psycho-oncology. In: Independent psychiatr. journ.). Nezavisimyy psikhiatr. zhurn. 1995; 4: 9–17.]
  58. Caraceni A., Grassi L. Delirium: acute confusional states in palliative medicine. Oxford, 2003.
  59. Levenson J.A., Lesko L.M. Psychiatric aspects of adult leukemia. Semin. Oncol. Nurs. 1990; 6(1): 76–83.
  60. Moulaert P. Treatment of acute nonspecific delirium with i.v. haloperidol in surgical intensive care patients. Acta Anaesthesiol. Belg. 1989; 40(3): 183–6.
  61. Meagher D.J. Delirium: optimising management. BMJ 2001; 322: 144–9.
  62. Pjevic M., Kolak R., Komarcevic M. Sedation and analgesia in intensive therapy. Med. Pregl. 1998; 51(11–12): 509–17.
  63. Menza M.A., Murray G.B., Holmes V.F. et al. Controlled study of extrapyramidal reactions in the management of delirious, medically ill patients: intravenous haloperidol versus intravenous haloperidol plus benzodiazepines. Heart Lung 1988; 17(3): 238–41.
  64. Mayo-Smith M.F. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA 1997; 278(2): 144–51.
  65. Руководство по гематологии. Т. 3. Под ред. А.И. Воробьева. М., 2005. [Rukovodstvo po gematologii. T. 3. Pod red. A.I. Vorobyeva (Manual of hematology. Vol. 3. Ed. by: A.I. Vorobyev). M., 2005.]
  66. Добровольский А.В., Дробижев М.Ю. Психотропные средства у пациентов с соматическими заболеваниями. Сообщение 1. Журн. неврол. и психиатр. 1998; 98(7): 53–62. [Dobrovolskiy A.V., Drobizhev M.Yu. Psikhotropnye sredstva u patsiyentov s somaticheskimi zabolevaniyami. Soobshcheniye 1 (Psychotropic agents in patients with somatic disorders. Report 1. In: Journ. of neurol. & psychiatry). Zhurn. nevrol. i psikhiatr. 1998; 98(7): 53–62.]
  67. Дробижев М.Ю., Добровольский А.В. Психотропные средства у пациентов с соматическими заболеваниями. Сообщение 2. Журн. неврол. и психиатр. 1998; 98(8): 57–65. [Drobizhev M.Yu., Dobrovolskiy A.V. Psikhotropnye sredstva u patsiyentov s somaticheskimi zabolevaniyami. Soobshcheniye 2 (Psychotropic agents in patients with somatic diseases. Report 2. In: Journ. of neurol. & psychiatry). Zhurn. nevrol. i psikhiatr. 1998; 98(8): 57–65.]
  68. Бескова Д.А., Сиранчиева О.А. Дифференцированный подход к выбору метода психотерапии нозогенных реакций на госпитальном этапе лечения онкологических заболеваний. Псих. расстройства в общей мед. 2009; 1: 46–52.
  69. [Beskova D.A., Siranchiyeva O.A. Differentsirovannyy podkhod k vyboru metoda psikhoterapii nozogennykh reaktsiy na gospitalnom etape lecheniya onkologicheskikh zabolevaniy (Differentiated approach to choice of psychotherapeutic technique for nozogenic reactions at hospital stage of cancer patients management. In: Mental disorders in general med.). Psikh. rasstroystva v obshchey med. 2009; 1: 46–52.]

 

Current therapies for AL amyloidosis: literature review and our data

LYMPHOID TUMORS , , ,

A.G. Smirnova1, S.N. Bondarenko1, A.A. Kisina2, A.V. Smirnov2, A. Tsander 3, and B.V. Afanasyev1

1 R.M. Gorbacheva Institute of Pediatric Hematology and Transplantology, I.P. Pavlov State Medical University, Saint Petersburg, Russian Federation

2 Research Institute of Nephrology, I.P. Pavlov State Medical University, Saint Petersburg, Russian Federation

3 Universitare Transplantations-Centrum, Universitatsklinikum Hamburg-Eppendorf, Hamburg, Germany

ABSTRACT

AL amyloidosis is a relatively rare condition belonging to plasma cell dyscrasias with very heterogeneous clinical presentation and poor prognosis. This article presents a brief description of AL amyloidosis, current therapies, and our own statistics on new combination therapy outcomes. We included 46 patients with confirmed AL amyloidosis who received autologous stem cell transplantation and standard combination chemotherapy, including melphalan + dexamethasone or bortezomib + dexamethasone.

Keywords: AL amyloidosis, therapy, hematopoietic stem cell transplantation, melphalan, bortezomib.

 Read in PDF (RUS) pdficon

REFERENCES

  1. Falk R.H., Comenzo R.L., Skinner M. The systemic amyloidoses. N. Engl. J. Med. 1997; 337: 898–909.
  2. Kyle R.A., Gertz M.A. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin. Hematol. 1995; 32: 45–59.
  3. Dispenzieri A., Gertz M.A., Kyle R.A. et al. Prognostication of survival using cardiac troponins and N-terminal pro-brain natriuretic peptide in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2004; 104: 1881–7.
  4. Dispenzieri A., Gertz M.A., Kyle R.A. et al. Serum cardiac troponins and N-terminal pro-brain natriureticpeptide: a staging system for primary systemic amyloidosis. J. Clin. Oncol. 2004; 22: 3751–7.
  5. Palladini G., Merlini G. Transplantation vs. conventional-dose therapy for amyloidosis. Curr. Opt. Oncol. 2011; 23: 214–20.
  6. Palladini G., Lavatelli F., Russo P. et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006; 107: 3854–8.
  7. Bochtler T., Hegenbart U., Heiss C. et al. Evaluation of the serum-free light chain test in untreated patients with AL amyloidosis. Haematologica 2008; 93: 459–62.
  8. Dispenzieri A., Lacy M.Q., Katzmann J.A. et al. Absolute values of immunoglobulin free light chains are prognostic in patients with primary systemic amyloidosis undergoing peripheral blood stem cell transplantation. Blood 2006; 107: 3378–83.
  9. Kumar S., Dispenzieri A., Katzmann J.A. et al. Serum immunoglobulin free light-chain measurement in primary amyloidosis: prognostic value and correlations with clinical features. Blood 2010; 116(24): 5126–9.
  10. Lachmann H.J., Gallimore R., Gillmore J.D. et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy. Br. J. Haematol. 2003; 122: 78–84.
  11. Gertz M.A. Definition of organ involvement and response to treatment in AL amyloidosis: An updated consensus opinion. Amyloid 2010; 17(Suppl. 1): 48–49, abstr. CP-B.
  12. Leung N., Dispenzieri A., Lacy M.Q. et al. Severity of Baseline Proteinuria Predicts Renal Response in Immunoglobulin Light Chain–Associated Amyloidosis after Autologous Stem Cell Transplantation. Clin. J. Am. Soc. Nephrol. 2007; 2: 440–4.
  13. Kyle R.A., Gertz M.A., Greipp Ph.R. et al. Long-term survival (10 years or more) in 30 patients with AL amyloidosis. Blood 1999; 93: 1062–6.
  14. Kyle R.A., Greipp, P.R. Primary systemic amyloidosis: comparison of melphalan and prednisone versus placebo. Blood 1978; 52: 818–27.
  15. Kyle R.A., Greipp, P.R., O’Fallon M. Primary systemic amyloidosis: multivariate analysis for prognostic factors in 168 cases. Blood 1986; 68: 220–4.
  16. Kyle R.A., Gertz M.A., Greipp P.R. et al. A trial of three regimen for primary amyloidosis: colchicine alone, melphalan and prednisolone, and melphalan, prednisolone, and colchicine. N. Engl. J. Med. 1997; 336: 1202–7.
  17. Skinner M., Anderson J., Simms R. et al. Treatment of 100 patients with primary amyloidosis: a randomized trial of melphalan, prednisone, and colchicine versus colchicine only. Am. J. Med. 1996; 100: 290–8.
  18. Dhodapkar M.V., Hussein M.A., Rasmussen E. et al. Clinical efficacy of high-dose dexamethasone with maintenance dexamethasone/alpha interferon in patients with primary systemic amyloidosis: results of United States Intergroup Trial Southwest Oncology Group (SWOG) S9628. Blood 2004; 104: 3520–6.
  19. Palladini G., Perfetti V., Obici L. et al. Association of melphalan and highdose dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are ineligible for stem cell transplantation. Blood 2004; 103: 2936–8.
  20. Dispenzieri A., Lacy M.Q., Rajkumar S.V. et al. Poor tolerance of thalidomide in patients with primary systemic amyloidosis. Amyloid 2003; 10: 257–61.
  21. Palladini G., Perfetti V., Perlini S. et al. The combination of thalidomide and intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary amyloidosis (AL). Blood 2005; 105: 2949–51.
  22. Wechalekar А., Goodman H.J.B., Lachmann H.J. et al. Safety and efficacy of risk-adapted cyclophosphamide, thalidomide, and dexamethasone in systemic AL amyloidosis. Blood 2007; 109: 457–64.
  23. Dispenzieri A., Lacy M.Q., Zeldenrust S.R. et al. The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosis. Blood 2007; 109: 465–70.
  24. Sanchorawala V., Wright D.G., Rosenzweig M. et al. Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial. Blood 2007; 109: 492–6.
  25. Dispenzieri A., Gertz M.A., Hayman S.R. et al. Pomalidomide and dexamethasone for previously treated AL: a phase 2 study. Amyloid J. Protein Folding Dis. 2010; 17: 87.
  26. Dispenzieri A., Buadi F., Laumann K. et al. The activity of pomalidomide in patients with immunoglobulin light chain amyloidosis. Blood 2012; 119: 5397–404.
  27. Wechalekar A., Lachmann H.J., Offer M. et al. Efficacy of bortezomib in systemic AL amyloidosis with relapsed/refractory clonal disease. Haematologica 2008; 93(2): 295–8.
  28. Kastritis E., Anagnostopoulos A., Roussou M. et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone. Haematologica 2007; 92: 1351–8.
  29. Zonder J.A., Sanchorawala V., Snyder R.M. et al. Melphalan and Dexamethasone Plus Bortezomib Induces Hematologic and Organ Responses in AL-Amyloidosis with Tolerable Neurotoxicity. Blood 2009; 114: 310–1.
  30. Zonder J., Sanchorawala V., Snyder R. et al. Rapid haematologic and organ responses in patients with AL amyloid treated with bortezomib plus melphalan and dexamethasone. Amyloid J. Protein Folding Dis. 2010; 17: 86–7.
  31. Mikhael J.R., Schuster S.R., Jimenez-Zepeda V.H. et al. The Combination of Cyclophosphamide-Bortezomib-Dexamethasone (CYBOR-D) Is a Highly Effective and Well Tolerated Regimen that Produces Rapid and Complete Hematological Response In Patients with AL Amyloidosis. ASH Annual Meeting Abstracts 2010; 116: 3063.
  32. Comenzo R.L., Vosburgh E., Simms R.W. et al. Dose-intensive melphalan with blood stem cell support for the treatment of AL amyloidosis: One-year follow-up in five patients. Blood 1996; 88: 2801–6.
  33. Comenzo R.L., Vosburgh E., Falk R.H. et al. Dose intensive melphalan with blood stem-cell support for the treatment of AL (amyloid light-chain) amyloidosis: survival and responses in 25 patients. Blood 1998; 91: 3662–70.
  34. Moreau P., Leblond V., Bourquelot P. et al. Prognostic factors for survival and response after high-dose therapy and autologous stem cell transplantation in systemic AL amyloidosis: a report on 21 patients. Br. J. Haematol. 1998; 101: 766–9.
  35. Gillmore J.D. High-dose melphalan and stem cell rescue for AL amyloidosis. In: Amyloid and Amyloidosis. Ed. by R.A. Kyle, M.A. Gertz). Pearl River: Parthenon Publishing, 1999: 102–4.
  36. Gertz M.A., Lacy M.Q., Gastineau D.A. et al. Blood stem cell transplantation as therapy for primary systemic amyloidosis (AL). Bone Marrow Transplant. 2000; 26: 963–9.
  37. Sanchorawala V. An overview of the use of high dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis. Bone Marrow Transplant. 2001; 28: 637–42.
  38. Skinner M., Sanchorawala V., Seldin D.C. et al. High-dose melphalan and autologous stem-cell transplantation in patients with AL amyloidosis: an 8-year study. Ann. Intern. Med. 2004; 140: 85–93.
  39. Dispenzieri A., Kyle R.A., Lacy M.Q. et al. Superior survival in primary systemic amyloidosis patients undergoing peripheral blood stem cell transplantation: a case-control study. Blood 2004; 103: 3960–3.
  40. Schonland S.O. Current status of hematopoietic cell transplantation in the treatment of systemic amyloid light-chain amyloidosis. Bone Marrow Transplant. 2011 Jul 25: 1–11.
  41. Gertz M.A., Lacy M.Q., Dispenzieri A. et al. Stem cell transplantation for the management of primary systemic amyloidosis. Am. J. Med. 2002; 113: 549–55.
  42. Comenzo R.L., Gertz M.A. Autologous stem cell transplantation for primary systemic amyloidosis. Blood 2002; 99: 4276–82.
  43. Cibeira M.T., Sanchorawala V., Seldin D.C. et al. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients. Blood 2011; 118(16): 4346–52.
  44. Sanchorawala V., Wright D.G., Quillen K. et al. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis. Bone Marrow Transplant. 2007; 40: 557–62.
  45. Quillen K., Seldin D.C., Finn K.T., Sanchorawala V. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis. Bone Marrow Transplant. 2011; 46: 976–80.
  46. Cohen A.D., Zhou P., Reich L. et al. Adjuvant dexamethasone (D) ± thalidomide (T) improves hematologic and organ responses after risk-adapted high-dose melphalan with autologous stem cell transplant (SCT) for patients with systemic AL amyloidosis (AL) [abstract]. Blood 2005; 106: 340a, abstr. 1163.
  47. Landau H., Hassoun H., Rosenzweig M.A. et al. Maintained Hematologic and Organ Responses at Two Years Following Stem Cell Transplant In Systemic Light-Chain Amyloidosis (AL) Using Short-Course Bortezomib and Dexamethasone Consolidation Therapy. ASH Annual Meeting Abstracts 2010; 116: 2391.
  48. Sanchorawala V., Wright D.G., Seldin D.C. et al. High-dose intravenous melphalan and autologous stem cell transplantation as initial therapy or following two cycles of oral chemotherapy for the treatment of AL amyloidosis: results of a prospective randomized trial. Bone Marrow Transplant. 2004; 33: 381–8.
  49. Perz J.B., Schonland S.O., Hundemer M. et al. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study. Br. J. Haematol. 2004; 127: 543–51.
  50. Schonland S.O., Lokhorst H., Buzyn A. et al. Allogeneic and syngeneic hematopoietic cell transplantation in patients with amyloid light-chain amyloidosis: a report from the European Group for Blood and Marrow Transplantation. Blood 2006; 107: 2578–84.
  51. Lewis W.D., Skinner M., Simms R.W. et al. Orthotopic liver transplantation for familial amyloidotic polyneuropathy. Clin. Transplant. 1994; 8: 107–10.
  52. Holmgren G., Ericzon B.G., Groth C.G. et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis. Lancet 1993; 341: 1113–6.
  53. Gillmore J.D., Goodman H.J., Lachmann H.J. et al. Sequential heart and autologous stem cell transplantation for systemic AL amyloidosis. Blood 2006; 107: 1227–9.
  54. Isoniemi H., Kyllonen L., Ahonen J. et al. Improved outcome of renal transplantation in amyloidosis. Transpl. Int. 1994; 7(Suppl. 1): S298–300.
  55. Hrncic R., Wall J., Wolfenbarger D.A. et al. Antibody-mediated resolution of light chain-associated amyloid deposits. Am. J. Pathol. 2000; 157: 1239–46.
  56. Zhou P., Comenzo R.L. CD32B is highly expressed on clonal plasma cells from patients with systemic light-chain amyloidosis and provides a target for monoclonal antibody-based therapy. Blood 2008; 111: 3403–6.
  57. Palladini G. Dispenzieri A., Gertz M.A. et al. Validation of the criteria of response to treatment in AL amyloidosis. Blood 2010; 116: 1364a.